Ramiven — Abemaciclib
Abemaciclib is an oral CDK4/6 inhibitor that's changed how a large segment of breast cancer is treated by allowing patients to manage hormone-receptor-positive disease with twice-daily tablets rather than repeated hospital visits for IV chemotherapy — a genuine quality-of-life and treatment-adherence advantage that also happens to make it a far simpler product for distributors to bring into markets with limited infusion-center access.
- Approved indications: Hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer, typically combined with an aromatase inhibitor or fulvestrant
- Mechanism: Inhibits CDK4 and CDK6, proteins that drive cancer-cell division, halting tumor cell-cycle progression
- Administration: Oral tablet, taken twice daily — continuous dosing rather than cyclical, unlike traditional chemotherapy
- Combination therapy: Given alongside hormone therapy (aromatase inhibitors or fulvestrant), not chemotherapy
Key Product Facts
50mg, 100mg, 150mg tablets
Strength
14 tablets/strip
Pack Size
Abemaciclib
Active Ingredient
Oncology
Category
On Request
Availability
Abemaciclib is an oral CDK4/6 inhibitor that's changed how a large segment of breast cancer is treated by allowing patients to manage hormone-receptor-positive disease with twice-daily tablets rather than repeated hospital visits for IV chemotherapy — a genuine quality-of-life and treatment-adherence advantage that also happens to make it a far simpler product for distributors to bring into markets with limited infusion-center access.
- Approved indications: Hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer, typically combined with an aromatase inhibitor or fulvestrant
- Mechanism: Inhibits CDK4 and CDK6, proteins that drive cancer-cell division, halting tumor cell-cycle progression
- Administration: Oral tablet, taken twice daily — continuous dosing rather than cyclical, unlike traditional chemotherapy
- Combination therapy: Given alongside hormone therapy (aromatase inhibitors or fulvestrant), not chemotherapy
- Diarrhea: The most common side effect, occurring in a majority of patients — proactive anti-diarrheal management protocol is standard practice from treatment initiation
- Neutropenia: Requires regular complete blood count monitoring, particularly in the first few months of treatment
- Hepatotoxicity: Liver function monitoring recommended
- VTE risk: Elevated risk of blood clots — patients should be counseled on symptoms
- Pregnancy: Contraindicated
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| MSDS |
? Standard |
Stock status: Available on request | Quote turnaround: 24 hours
- Logistics: Standard export logistics, no cold chain required
- Coverage: Global export markets
- Tracking: Full shipment tracking included
What is Abemaciclib used for?
Treats hormone-receptor-positive, HER2-negative advanced breast cancer, usually combined with hormone therapy.
Get Abemaciclib price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
Is it chemotherapy?
No, it's a targeted oral therapy that blocks specific proteins driving cancer cell division, taken as a twice-daily tablet.
What's the most common side effect?
Diarrhea, which is typically managed proactively with anti-diarrheal medication from the start of treatment.
Who supplies Abemaciclib from India?
WHO-GMP certified tablet manufacturing with full export documentation.
